Metabolic Syndrome Market size was valued at USD 128.1 billion in 2024 and is anticipated to reach USD 322.8 billion by the end of 2037, expanding at a CAGR of 8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of metabolic syndrome is estimated at USD 138.4 billion.
The metabolic syndrome market is likely to expand at a steady rate due to rising diseases among people, such as obesity, type 2 diabetes, and cardiovascular diseases. Due to these complex diseases, the need for novel therapeutic strategies to cover early intervention and personalized care is rising. In November 2023, Cleerly launched the TRANSFORM trial, a major study of patients with metabolic syndrome, pre-diabetes, or type 2 diabetes, to demonstrate personalized care strategies. Such initiatives are reflecting the industry's focus on preventive care and personalized treatment approaches while underlining opportunities for growth, as health systems show a keen interest in managing metabolic health.
Governments around the world consider metabolic syndrome a top-priority public health issue, and this forms the purpose of education campaigns along with periodic health checkups. For example, Japan Ministry of Health started a ten-year campaign in March 2023 to reduce metabolic syndrome's prevalence through healthier lifestyles and preventing the risk factors associated with metabolic syndrome. Such government programs are driving the adoption of lifestyle interventions and pharmaceutical treatments, thereby driving demand in the metabolic syndrome market. The global focus on public awareness and preventive measures entails a call for metabolic health management as one of the priorities in healthcare systems.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8% |
|
Base Year Market Size (2024) |
USD 128.1 billion |
|
Forecast Year Market Size (2037) |
USD 322.8 billion |
|
Regional Scope |
|
Treatment (Pharmaceuticals, Surgery, Lifestyle Management)
The pharmaceuticals segment is expected to capture metabolic syndrome market share of over 38% by 2037. The demand for strong medicines that can address major factors like obesity, diabetes, or high cholesterol is expected to boost this growth. In March 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration had extended the indication of the usage of Evkeeza (evinacumab-dgnb) in addition to other lipid-lowering therapies in pediatric patients 5–11 years of age with homozygous familial hypercholesterolemia. This underlines new medicines that aim particularly at managing metabolic risk factors.
Type of Metabolic Syndrome (Type 1 Metabolic Syndrome, Type 2 Metabolic Syndrome, Type 3 Metabolic Syndrome)
In metabolic syndrome market, Type 2 metabolic syndrome segment is set to capture revenue share of over 54.5% by 2037 due to the coverage of obesity, high cholesterol, and insulin resistance. The wide prevalence of type 2 diabetes worldwide accelerates demand for its comprehensive management. For example, Eli Lilly announced in April 2023 that data from the SURMOUNT-2 study were presented in patients with type 2 diabetes and obesity who saw a weight reduction. The presented data underlined the demand for targeted solutions in the management of type 2 metabolic syndrome.
Our in-depth analysis of the metabolic syndrome market includes the following segments
|
Treatment |
|
|
Type of Metabolic Syndrome |
|
|
Risk Factors |
|
North America Market Analysis
By 2037, North America metabolic syndrome market is projected to hold more than 35% revenue share, due to the region's high prevalence of obesity and rising awareness about preventive care. The presence of advanced healthcare infrastructure in the region, with a strong emphasis on managing metabolic health especially, drives the market forward. Early detection and curative treatment are driving the growth in both the U.S. and Canada market.
The U.S. metabolic syndrome market is driven by huge investments in R&D and significant awareness programs related to obesity and diabetes. In February 2022, AliveCor introduced the KardiaMobile Card which is a thin, credit-card-sized ECG device offering a medical-grade, single-lead ECG in 30 seconds in a single tap that makes heart health monitoring even easier and accessible. Globally, many awareness programs highlight early testing and options for the treatment of metabolic diseases. This underlines the stress on novelty and early management of health in the U.S.
Canada represents a growing metabolic syndrome market, with government-backed public health campaigns aimed at early screening and preventive care. The public health campaigns initiated by Health Canada on obesity and diabetes reflect the government's commitment to ensure the control of metabolic syndrome prevalence. With the increasing adoption of lifestyle and pharmaceutical solutions, Canada continues to be one of the strong contributors to the metabolic syndrome market in North America.
Asia Pacific Market Analysis
Asia Pacific metabolic syndrome market is anticipated to register growth of around 9.5% from 2025 to 2037, due to growing instances of lifestyle diseases and rising healthcare expenditures in countries like India, China, and Japan. Government initiatives regarding obesity and diabetes also act as an added factor that can enhance the potential growth of the market. Additionally, advancements in healthcare infrastructure and increasing accessibility to diagnostic tools are likely to fuel further growth.
The metabolic syndrome market is also gaining momentum in India, with increasing trends of obesity and diabetes, supplemented by government investments in public health. The government of India commitment to preventive care can be seen in initiatives aimed at metabolic health awareness. In May 2022, Sun Pharma launched Brillo, an LDL-lowering drug, in India. This underlined the pharmaceutical industry's contribution toward the reduction of metabolic syndrome risk factors. All these factors mentioned above push the market toward accessible treatments and open lucrative investment prospects for players.
China is also witnessing steady growth in the metabolic syndrome market as addressing lifestyle-related diseases remains one of the key focuses. The market growth is supported by healthcare reforms, coupled with improved public health awareness campaigns. The increasing prevalence of diabetes and obesity in China increased the demand for metabolic health solutions. In October 2022, InBody presented its BWA 2.0 body water analyzer for metabolic health management through the assessment of body composition. Such developments align with the country's attention toward advanced diagnostic tools to address metabolic syndrome.
The metabolic syndrome market is highly competitive, comprising multinational companies such as Johnson & Johnson, Bayer, Eli Lilly, Amgen, Merck, Takeda, Abbott Laboratories, Pfizer, AstraZeneca, Roche, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, and Novo Nordisk driving the industry. Thus, these firms have emphasized R&D for the development of new methods of treatment focused on pharmaceuticals, lifestyle management, diagnostics, and the development of tools. Strategic partnerships by leading players can enable them to further increase their presence within the market and widen access to better treatments for patients.
In November 2022, Provention Bio made history when its teplizumab became the world's first-ever preventive treatment for type 1 diabetes approved by the FDA. New, targeted, and preventive treatments are increasingly confronting troublesome symptoms of metabolic disease. Competition is anticipated to increase even more with innovative approaches from major players as they try to provide comprehensive solutions that address metabolic syndrome and improve outcomes.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?